Rapport Therapeutics (NASDAQ: RAPP) plans insider sale of 2,092 shares

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. (RAPP) received a Form 144 notice indicating that officer Krishnaswamy Yeleswaram plans to sell up to 2,092 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 08/19/2026.

The shares were acquired upon vesting of restricted stock units between 06/09/2024 and 02/09/2025 and are described as Founders Shares. The filing lists an aggregate market value of about $102,528.92 for the planned sale and reports 47,978,286 shares of common stock outstanding.

Key Figures

Shares to be sold: 2,092 shares Aggregate market value of planned sale: $102,528.92 Shares outstanding: 47,978,286 shares +2 more

5 metrics

Shares to be sold 2,092 shares Planned sale of common stock under Rule 144

Aggregate market value of planned sale $102,528.92 Value associated with 2,092 shares to be sold

Shares outstanding 47,978,286 shares Common stock outstanding for Rapport Therapeutics, Inc.

Approximate sale date 08/19/2026 Planned date for sale of common shares

Initial acquisition date 06/09/2024 Date common shares were acquired as Founders Shares

Key Terms

Rule 144, restricted stock units, Founders Shares, control securities

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"acquired upon the vesting of restricted stock units during the period"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Founders Shares financial

"Common | 06/09/2024 | Founders Shares | Issuer"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

control securities financial

"securities are to be sold for the account of the person filing this notice under Rule 144 control"

FAQ

What does the Form 144 filing mean for Rapport Therapeutics (RAPP)?

The Form 144 reports an officer’s intent to sell up to 2,092 RAPP shares under Rule 144. It is a notice of a potential resale of restricted or control securities, not an offering by Rapport Therapeutics itself and does not change the company’s capital structure directly.

How many Rapport Therapeutics (RAPP) shares are planned to be sold in this Form 144?

The filing states a planned sale of 2,092 shares of RAPP common stock. These shares are valued in the notice at an aggregate market value of about $102,528.92 and are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

Who is selling RAPP shares according to this Form 144 notice?

The notice lists Krishnaswamy Yeleswaram, an officer of Rapport Therapeutics, as the person for whose account the securities will be sold. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.

When were the RAPP shares in this Form 144 acquired and how?

The common shares to be sold were acquired on 06/09/2024 as Founders Shares. A remark explains the securities were acquired upon the vesting of restricted stock units during the period from 06/09/2024 through 02/09/2025.

What is the approximate sale date and market venue for the RAPP shares in this filing?

The planned sale date in the notice is 08/19/2026. The filing identifies the market as NASDAQ and names Morgan Stanley Smith Barney LLC Executive Financial Services in New York as the broker handling the transaction.

How many Rapport Therapeutics (RAPP) shares are reported outstanding in the Form 144?

The Form 144 lists 47,978,286 shares of RAPP common stock outstanding. This figure provides context for the company’s equity base and is separate from the 2,092 shares that the officer has notified for potential sale under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 04:38 PM Accepted by SEC EDGAR 08/19/2026 - 04:38 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002022156
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Rapport Therapeutics, Inc.
SEC File Number	001-42121
Address of Issuer	99 High Street, Suite 2100 Boston MASSACHUSETTS 02110
Phone	8573218020
Name of Person for Whose Account the Securities are To Be Sold	KRISHNASWAMY YELESWARAM
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2092	102528.92	47978286	08/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/09/2024	Founders Shares	Issuer			2092	06/09/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 06/09/2024 through 02/09/2025.
Date of Notice	08/19/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Krishnaswamy Yeleswaram
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)